钇-90微球选择性内放射治疗在肝细胞癌降期转化中的研究进展  

Research progress of Yttrium-90 microsphere selective internal radiation therapy in downstaging and conversion of hepatocellular carcinoma

作　　者：梁礼聪 梁钰婵 黄文薮 郭永建 黄敬君 林立腾 蔡明岳 朱康顺 LIANG Licong;LIANG Yuchan;HUANG Wensou;GUO Yongjian;HUANG Jingjun;LIN Liteng;CAI Mingyue;ZHU Kangshun(Department of Minimally Invasive Interventional Radiology,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510245,Guangdong,China)

机构地区：[1]广州医科大学附属第二医院微创介入科,广州510245

出　　处：《中国临床医学》2025年第1期9-14,共6页Chinese Journal of Clinical Medicine

基　　金：广州地区临床高新和重大技术项目。

摘　　要：中国肝细胞癌(hepatocellular carcinoma,HCC)的发病率和死亡率均位居世界前列,造成了沉重的社会负担。肝切除术和肝移植手术是HCC根治性治疗的主要手段,但多数患者在初诊时已无法满足手术条件。钇-90微球选择性内放射治疗(Yttrium-90 microsphere selective internal radiation therapy,^(90)Y-SIRT)具有强效缩瘤、增大余肝、消退门静脉癌栓、改善患者生活质量等优势,可安全有效地应用于HCC的转化、降期以及手术的桥接治疗,帮助患者重获根治性治疗的机会,并降低术后复发率。本综述主要阐述^(90)Y-SIRT在此领域的临床应用及研究进展。The incidence and mortality of hepatocellular carcinoma(HCC)in China are among the highest in the world,imposing a heavy social burden.Liver resection and liver transplantation are the primary radical treatments for HCC,although most patients are no longer able to meet the surgical requirements at initial diagnosis.Yttrium-90 microsphere selective internal radiation therapy(^(90)Y-SIRT)has the advantages of shrinking tumors,enlarging residual liver,regressing portal vein tumor thrombus and improving the quality of life,which can be used for conversion,downstaging and bridging therapy for HCC before surgical treatment,enabling patients regain the chance of radical treatment and reducing the postoperative recurrence rate.This review focuses on the clinical application and progress of^(90)Y-SIRT in this field.

关 键 词：肝细胞癌 钇-90 选择性内放射治疗 降期治疗 转化治疗 桥接治疗 

分 类 号：R735.7[医药卫生—肿瘤]